JP2009524631A - 薬剤輸送システム - Google Patents
薬剤輸送システム Download PDFInfo
- Publication number
- JP2009524631A JP2009524631A JP2008551857A JP2008551857A JP2009524631A JP 2009524631 A JP2009524631 A JP 2009524631A JP 2008551857 A JP2008551857 A JP 2008551857A JP 2008551857 A JP2008551857 A JP 2008551857A JP 2009524631 A JP2009524631 A JP 2009524631A
- Authority
- JP
- Japan
- Prior art keywords
- caged
- drug
- target site
- label
- radiation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/52—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an inorganic compound, e.g. an inorganic ion that is complexed with the active ingredient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N2/00—Magnetotherapy
- A61N2/004—Magnetotherapy specially adapted for a specific therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0042—Photocleavage of drugs in vivo, e.g. cleavage of photolabile linkers in vivo by UV radiation for releasing the pharmacologically-active agent from the administered agent; photothrombosis or photoocclusion
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6925—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a microcapsule, nanocapsule, microbubble or nanobubble
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N2/00—Magnetotherapy
- A61N2/06—Magnetotherapy using magnetic fields produced by permanent magnets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/906—Drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Ophthalmology & Optometry (AREA)
- Radiology & Medical Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Ceramic Engineering (AREA)
- Nanotechnology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
【解決手段】磁気部分、及びそれに結合しているケージド(caged)薬剤を含んでなり、当該薬剤が、所定の波長及び/又は強度の放射線に反応して活性化及び/又は放出されうる、薬剤輸送システム。患者に前記システムを投与するステップと、磁場の印加によって標的部位に前記システムを局在化するステップと、標的部位に所定の波長及び/又は強度の放射線を照射し、標的部位で当該ケージド薬剤を活性化させ、放出させるステップを含んでなる、前記システムの使用若しくは薬剤輸送システム。
【選択図】図1
Description
置換された(2−)ニトロベンジル、ジメトキシニトロベンジル、ニトロベラトリルオキシカルボニル、2−(ジメチルアミノ)−5−ニトロフェニル、ビス(o−ニトロフェニル)エタンジオール、臭素化ヒドロキシキノリン、クマリン−4−イルメチル誘導剤、7−ニトロインドリン、ベンゾフェノン、アジリジン、有機ルテニウム(II)錯体。ケージング基は、光変化しやすい架橋結合基であってもよい。上記の基の例としては、限定されないがα−メチル2−ニトロベンジル基を有するアミノ、ヒドロキシ、ブロモ及びメチルアミノ基、並びに、4−ニトロフェノキシカルボニル基で活性化されたOH及びNH2基が挙げられる。
12 光活性化型ケージド薬剤
14 磁気ナノ粒子
16 発光標識
R 治療薬
Claims (16)
- 磁気部分及びそれに結合するケージド薬剤を含んでなり、薬剤が、所定の波長及び/又は強度の放射線に反応して活性化及び/又は放出されうる、薬剤輸送システム。
- 更に標識を含んでなる、請求項1記載のシステム。
- 当該標識が発光である、請求項2記載のシステム。
- 透明若しくは半透明の組織への薬剤輸送に適する、請求項1から3のいずれか1項記載のシステム。
- 眼内薬剤輸送システムである、請求項4記載のシステム。
- 前記磁気部分が1〜20nmのサイズの磁気コアを有する、請求項1から5のいずれか1項記載のシステム。
- 前記ケージド薬剤が光活性化型ケージド薬剤である、請求項1から6のいずれか1項記載のシステム。
- 薬剤輸送方法への、請求項1から7のいずれか1項記載のシステムの使用であって、前記方法が、患者に請求項1から7のいずれか1項記載のシステムを投与するステップと、磁場の印加によって標的部位に前記システムを局在化するステップと、標的部位に所定の波長及び/又は強度の放射線を照射し、標的部位で当該ケージド薬剤を活性化させ、放出させるステップを含んでなる、前記使用。
- 前記システムが非経口的に患者に投与される、請求項8記載の使用。
- 前記システムが経腸的に患者に投与される、請求項8記載の使用。
- 前記システムが発光標識を含んでなり、前記方法が更に、標的部位に所定の波長及び/又は強度の放射線を照射して標識を活性化させ、前記システムが標的部位に存在するか否かを確認するステップを含んでなる、請求項8から10のいずれか1項記載の使用。
- 外部磁場を用いて、標的部位で前記システムを局在化させる、請求項8から10のいずれか1項記載の使用。
- 薬剤輸送方法であって、患者に請求項1から6のいずれか1項記載のシステムを投与するステップと、磁場の印加により、標的部位で前記システムを局在化させるステップと、標的部位に所定の波長及び/又は強度の放射線を照射し、標的部位でケージド薬剤を活性化させ、放出させるステップを含んでなる方法。
- 前記システムが非経口的に患者に投与される、請求項13記載の方法。
- 前記システムが経腸的に患者に投与される、請求項13記載の方法。
- 前記システムが発光標識を含んでなり、前記方法が更に、標的部位に所定の波長及び/又は強度の放射線を照射して標識を活性化させ、前記システムが標的部位に存在するか否かを確認するステップを含んでなる、請求項13から15のいずれか1項記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0601502A GB2435211B (en) | 2006-01-25 | 2006-01-25 | Drug delivery system |
GB0601502.8 | 2006-01-25 | ||
PCT/GB2007/000187 WO2007085804A1 (en) | 2006-01-25 | 2007-01-22 | Drug delivery system |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2009524631A true JP2009524631A (ja) | 2009-07-02 |
JP5173835B2 JP5173835B2 (ja) | 2013-04-03 |
Family
ID=36060839
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008551857A Expired - Fee Related JP5173835B2 (ja) | 2006-01-25 | 2007-01-22 | 薬剤輸送システム |
Country Status (6)
Country | Link |
---|---|
US (2) | US8486440B2 (ja) |
EP (1) | EP1983949B1 (ja) |
JP (1) | JP5173835B2 (ja) |
CA (1) | CA2637279C (ja) |
GB (1) | GB2435211B (ja) |
WO (1) | WO2007085804A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013540745A (ja) * | 2010-09-20 | 2013-11-07 | ナノフタルミックス エルエルシー | 超常磁性特性を有するナノ粒子からなる医療用材料及びその外科手術における使用 |
JP2022508435A (ja) * | 2018-09-10 | 2022-01-19 | マツクス-プランク-ゲゼルシヤフト ツール フエルデルング デル ヴイツセンシヤフテン エー フアウ | 生体適合性マイクロスイマーの作製方法、マイクロスイマー、およびそのようなマイクロスイマーの使用方法 |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2435211B (en) | 2006-01-25 | 2009-08-26 | Alan Whitmore | Drug delivery system |
GB0810359D0 (en) | 2008-06-06 | 2008-07-09 | Univ Belfast | Composition |
US11890226B2 (en) * | 2009-02-25 | 2024-02-06 | University Of Maryland, College Park | Device and methods for directing agents into an eye |
US10159735B2 (en) | 2012-06-26 | 2018-12-25 | The Curators Of The University Of Missouri | Photocleavable drug conjugates |
WO2014074475A1 (en) * | 2012-11-07 | 2014-05-15 | Emmetrope Ophthalmics Llc | Magnetic eye shields and methods of treatment and diagnosis using the same |
ES2813365T3 (es) * | 2013-06-26 | 2021-03-23 | Univ Maryland | Sistema para dirigir agentes hacia dentro de un ojo |
WO2015089154A1 (en) * | 2013-12-10 | 2015-06-18 | The Regents Of The University Of California | Regionally activated drug delivery nanoparticles |
US9820690B1 (en) * | 2014-07-16 | 2017-11-21 | Verily Life Sciences Llc | Analyte detection system |
US10058505B2 (en) | 2015-03-22 | 2018-08-28 | Zeynab Mousavikhamene | Transscleral drug delivery |
US10918599B2 (en) | 2015-04-02 | 2021-02-16 | The Research Foundation For The State University Of New York | Serum-stable compositions and methods for light-triggered release of materials |
US20170209577A1 (en) * | 2016-01-22 | 2017-07-27 | Vardhaan S. Ambati | Directed delivery of active agents using quantum dots |
DK3245988T3 (da) | 2016-05-18 | 2024-01-29 | Sonikure Holdings Ltd | System til ultralydsforstærket transskleral levering af lægemidler |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001051087A2 (en) * | 2000-01-12 | 2001-07-19 | Light Sciences Corporation | Novel treatment for eye disease |
WO2003066066A1 (en) * | 2002-02-01 | 2003-08-14 | Vanderbilt University | Targeted drug delivery methods |
US20040166553A1 (en) * | 2002-11-18 | 2004-08-26 | Genospectra, Inc. | Caged sensors, regulators and compounds and uses thereof |
WO2005059158A2 (en) * | 2003-12-15 | 2005-06-30 | Dailey James P | Magnetized scleral buckle with polymerizing magnetic polymers |
WO2005095621A1 (ja) * | 2004-03-31 | 2005-10-13 | Genomidea Inc. | 人工磁性体による、遺伝子導入調節法およびシステム |
WO2005110397A1 (en) * | 2004-05-07 | 2005-11-24 | The Regents Of The University Of California | Treatment of myopia |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5448582A (en) | 1994-03-18 | 1995-09-05 | Brown University Research Foundation | Optical sources having a strongly scattering gain medium providing laser-like action |
AU3894595A (en) | 1994-11-08 | 1996-05-31 | Spectra Science Corporation | Semiconductor nanocrystal display materials and display apparatus employing same |
US5745882A (en) | 1995-01-09 | 1998-04-28 | Us West Marketing Resources Group, Inc. | Electronic classified advertising interface method and instructions with continuous search notification |
JP2001288200A (ja) * | 2000-03-31 | 2001-10-16 | Bunshi Biophotonics Kenkyusho:Kk | ケージド核移行シグナルペプチド、複合体及びそれを用いた物質の細胞核への導入方法 |
US20030191458A1 (en) * | 2002-04-03 | 2003-10-09 | Cornelius Diamond | Light-activated drug delivery method and device |
WO2004006765A1 (en) * | 2002-07-17 | 2004-01-22 | Dailey James P | Delivery of therapeutic agent affixed to magnetic particle |
JP5398982B2 (ja) * | 2004-05-24 | 2014-01-29 | ミダテック リミテッド | Rnaリガンドを含むナノ粒子 |
GB2435211B (en) | 2006-01-25 | 2009-08-26 | Alan Whitmore | Drug delivery system |
-
2006
- 2006-01-25 GB GB0601502A patent/GB2435211B/en not_active Expired - Fee Related
-
2007
- 2007-01-22 EP EP07704966.6A patent/EP1983949B1/en not_active Not-in-force
- 2007-01-22 US US12/162,180 patent/US8486440B2/en not_active Expired - Fee Related
- 2007-01-22 CA CA2637279A patent/CA2637279C/en not_active Expired - Fee Related
- 2007-01-22 JP JP2008551857A patent/JP5173835B2/ja not_active Expired - Fee Related
- 2007-01-22 WO PCT/GB2007/000187 patent/WO2007085804A1/en active Application Filing
-
2013
- 2013-07-11 US US13/939,528 patent/US8951547B2/en not_active Expired - Fee Related
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001051087A2 (en) * | 2000-01-12 | 2001-07-19 | Light Sciences Corporation | Novel treatment for eye disease |
WO2003066066A1 (en) * | 2002-02-01 | 2003-08-14 | Vanderbilt University | Targeted drug delivery methods |
US20040166553A1 (en) * | 2002-11-18 | 2004-08-26 | Genospectra, Inc. | Caged sensors, regulators and compounds and uses thereof |
WO2005059158A2 (en) * | 2003-12-15 | 2005-06-30 | Dailey James P | Magnetized scleral buckle with polymerizing magnetic polymers |
WO2005095621A1 (ja) * | 2004-03-31 | 2005-10-13 | Genomidea Inc. | 人工磁性体による、遺伝子導入調節法およびシステム |
WO2005110397A1 (en) * | 2004-05-07 | 2005-11-24 | The Regents Of The University Of California | Treatment of myopia |
Non-Patent Citations (1)
Title |
---|
JPN6012040430; Bioconjug Chem., (1998) 9[2] p.143-51. * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013540745A (ja) * | 2010-09-20 | 2013-11-07 | ナノフタルミックス エルエルシー | 超常磁性特性を有するナノ粒子からなる医療用材料及びその外科手術における使用 |
US9427354B2 (en) | 2010-09-20 | 2016-08-30 | Nanophthalmics, Llc | Material for medical use comprising nanoparticles with superparamagnetic properties and its utilization in surgery |
JP2022508435A (ja) * | 2018-09-10 | 2022-01-19 | マツクス-プランク-ゲゼルシヤフト ツール フエルデルング デル ヴイツセンシヤフテン エー フアウ | 生体適合性マイクロスイマーの作製方法、マイクロスイマー、およびそのようなマイクロスイマーの使用方法 |
Also Published As
Publication number | Publication date |
---|---|
GB2435211B (en) | 2009-08-26 |
EP1983949A1 (en) | 2008-10-29 |
US20130296632A1 (en) | 2013-11-07 |
US20090030261A1 (en) | 2009-01-29 |
CA2637279A1 (en) | 2007-08-02 |
CA2637279C (en) | 2013-04-23 |
US8486440B2 (en) | 2013-07-16 |
EP1983949B1 (en) | 2013-08-28 |
WO2007085804A1 (en) | 2007-08-02 |
GB0601502D0 (en) | 2006-03-08 |
GB2435211A (en) | 2007-08-22 |
US8951547B2 (en) | 2015-02-10 |
JP5173835B2 (ja) | 2013-04-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5173835B2 (ja) | 薬剤輸送システム | |
Vankayala et al. | Near‐infrared‐light‐activatable nanomaterial‐mediated phototheranostic nanomedicines: an emerging paradigm for cancer treatment | |
Yang et al. | Enhancement of photodynamic cancer therapy by physical and chemical factors | |
US9393396B2 (en) | Method and composition for hyperthermally treating cells | |
US10300299B2 (en) | Advanced methods and systems for treating cell proliferation disorders | |
US9662388B2 (en) | Methods and systems for treating cell proliferation disorders using plasmonics enhanced photospectral therapy (PEPST) and exciton-plasmon enhanced phototherapy (EPEP) | |
US9302087B2 (en) | Method and composition for hyperthermally treating cells | |
US9320813B2 (en) | Method and composition for hyperthermally treating cells | |
TWI741064B (zh) | 用於修飾介導生物活性或與生物活性有關之靶結構之醫藥組合物及套組 | |
US9662389B2 (en) | Functionalized metal-coated energy converting nanoparticles, methods for production thereof and methods for use | |
US20070218049A1 (en) | Nanoparticle based photodynamic therapy and methods of making and using same | |
US9289491B2 (en) | Method and composition for hyperthermally treating cells | |
US9017729B2 (en) | Method and composition for hyperthermally treating cells | |
Homayoni et al. | Combination of photodynamic therapy and nanotechnology: non-invasive weapon against cancer | |
US20150087973A1 (en) | Method and composition for hyperthermally treating cells | |
Patel et al. | Smart nanocomposite assemblies for multimodal cancer theranostics | |
Kotulska et al. | Advances in photodynamic therapy assisted by electroporation | |
Carlini et al. | Comparative anti-cancer properties of quantum dots and gold particles conjugated to chemotherapeutic agents | |
Maheswaran et al. | Theranostics an emerging paradigm—A review | |
US20170209577A1 (en) | Directed delivery of active agents using quantum dots | |
Králová et al. | Combined Therapy For Squamous Carcinoma Cells: Application of Porphyrin-Alkaloid Modified Gold Nanoparticles | |
Horák et al. | Carcinoma cellular uptake, imaging, and targeting by RGD-and TAT-conjugated upconversion and/or magnetic nanoparticles |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20090826 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120221 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120518 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120807 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20121108 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20121211 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20121227 |
|
LAPS | Cancellation because of no payment of annual fees |